» Articles » PMID: 19698277

Severe Community-acquired Pneumonia and PIRO: a New Paradigm of Management

Overview
Date 2009 Aug 25
PMID 19698277
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Appropriate antibiotic management and aggressive supportive therapy is not enough to improve survival in severe community-acquired pneumonia (sCAP), a systemic syndrome involving infectious organisms, inflammation, and coagulation systems. A sepsis severity staging system focused on predisposition, insult, deleterious response, and organ failure (PIRO) provides a useful basis for risk stratification and therapy. A new paradigm of management is suggested based on early identification of patients at risk, aggressive management, modulation of host response, and need for adjunctive therapy. The CAP-PIRO score is a new, simple tool stratifying patients in four categories and may be useful for early identification of patients who may benefit from adjunctive therapy.

Citing Articles

CAP-PIRO Scoring System's Performance in Predicting Prognosis and Severity of Community-Acquired Pneumonia: A Single-Center Prospective Study.

Zhang X, Yang L, Wu J, Mei X Infect Drug Resist. 2024; 17:5335-5346.

PMID: 39635291 PMC: 11616438. DOI: 10.2147/IDR.S497311.

References
1.
Bordon J, Peyrani P, Brock G, Blasi F, Rello J, File T . The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest. 2008; 133(3):618-24. DOI: 10.1378/chest.07-1322. View

2.
Vila-Corcoles A . Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?. Lancet Infect Dis. 2008; 8(7):405-6. DOI: 10.1016/S1473-3099(08)70134-8. View

3.
Laterre P, Macias W, Janes J, Williams M, Nelson D, Girbes A . Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. Crit Care. 2008; 12(5):R117. PMC: 2592745. DOI: 10.1186/cc7011. View

4.
Restrepo M, Mortensen E, Waterer G, Wunderink R, Coalson J, Anzueto A . Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2008; 33(1):153-9. DOI: 10.1183/09031936.00054108. View

5.
Restrepo M, Bienen T, Mortensen E, Anzueto A, Metersky M, Escalante P . Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia: current practice survey. Chest. 2008; 133(3):828-9. DOI: 10.1378/chest.07-2887. View